Prf Technologies Ltd (PRFX) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Prf Technologies Ltd   (NASDAQ: PRFX)

Prf Technologies Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Prf Technologies Ltd in the fourth quarter 2025?
Prf Technologies Ltd recorded a cumulative net loss of $-5 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -56.48%.

Within the Major Pharmaceutical Preparations industry 222 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3886, from total ROE ranking in the third quarter 2025 at 3987.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 368.37 % 409.32 % - 409.32 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -5 -15 -15 -15 -15
Return On Equity (TTM) -56.48 % -202.28 % -272.92 % -535.49 % -1700.73 %
PRFX's Total Ranking # 3886 # 3987 # # #
Equity (TTM) in Millions 9 9 8 9 2
Seq. Equity Change -8.04 % 10.03 % -9.12 % 409.32 % 0 %
Seq. Net Income Change - - - - -

Back to PRFX Management Effectiveness >> PRFX's 5 Years Annual ROE >> Compare PRFX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 223
Sector # 509
Overall # 3886

Return On Equity Statistics
High Average Low
-40.07 %
-221.5 %
-799.78 %
(Dec 31 2021)   (Dec 31 2024)



  News about Prf Technologies Ltd Return on Equity ROE

Triumph Over Pain PainReforms Breakthrough in Postoperative Recovery Solutions,

PainReform, an innovative leader in drug delivery solutions, has recently announced a significant milestone in the development and successful manufacturing of new formulations aimed at providing enhanced postoperative care. These advanced formulations are designed to offer potent anti-inflammatory effects and extended analgesic relief, significantly improving patient outcomes during the critical phase of postoperative recovery. Key Developments PainReform s new formulations represent a considerable advancement in the field of postoperative pain management. The primary focus of these novel drugs is twofold: first, to reduce inflammation effectively, which is a common and often challenging aspect of post-surgery recovery; and second, to provide long-lasting pain relief, minimizing the need for frequent dosing and potentially reducing reliance on opioid painkillers.

PainReform CEO Ilan Hadar Discusses PRF-110's Potential in Combating the Opioid Epidemic


Introduction
In a recent interview with Proactiveinvestors.com, PainReform Ltd. s CEO, Ilan Hadar, shed light on the latest developments surrounding PRF-110 and its potential to address the concerning opioid epidemic. As a clinical-stage specialty pharmaceutical company, PainReform focuses on reformulating established therapeutics to provide safer and more effective solutions for pain management. This article explores the key insights shared by Hadar and highlights the significance of PRF-110 in tackling the current opioid crisis.
PainReform s Remarkable Progress
PainReform Ltd. has made significant strides in its mission to combat the opioid epidemic through the development of PRF-110. This novel drug is a long-lasting formulation of the commonly used anesthetic ropivacaine and holds great promise in offering prolonged pain relief without the risk of addiction associated with opioids.



PRFX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 9 2 7 11 18
Y / Y Equity Change 368.37 % -74.8 % -34.32 % -39.05 % 8.8 %
Net Income in Millions -5 -15 -9 -9 -7
Y / Y Net Income Change - - - - -
Return On Equity -58.78 % -799.78 % -129.08 % -79.77 % -40.07 %

Back to PRFX Management Effectiveness >> PRFX's 5 Years Annual ROE >> Compare PRFX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PRFX's' Return on Equity at Yahoo Finance
PRFX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PRFX's Competitors
Subscribers only: Roe for Prf Technologies Ltd 's Suppliers
Subscribers only: Return On Equity for PRFX's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE

Date modified: 2026-07-07T12:39:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.